WO2001054701A1 - Vaccination de personnes infectees par le vih apres une therapie antiretrovirale a haute activite - Google Patents

Vaccination de personnes infectees par le vih apres une therapie antiretrovirale a haute activite Download PDF

Info

Publication number
WO2001054701A1
WO2001054701A1 PCT/US2001/002766 US0102766W WO0154701A1 WO 2001054701 A1 WO2001054701 A1 WO 2001054701A1 US 0102766 W US0102766 W US 0102766W WO 0154701 A1 WO0154701 A1 WO 0154701A1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
virus
vaccine
cells
patient
Prior art date
Application number
PCT/US2001/002766
Other languages
English (en)
Other versions
WO2001054701A9 (fr
Inventor
David Ho
Martin Markowitz
Michel Klein
Raphaelle El Habib
Original Assignee
Aventis Pasteur, S.A.
Aaron Diamond Aids Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur, S.A., Aaron Diamond Aids Research Center filed Critical Aventis Pasteur, S.A.
Priority to AU2001233063A priority Critical patent/AU2001233063A1/en
Priority to US10/182,067 priority patent/US20040034209A1/en
Publication of WO2001054701A1 publication Critical patent/WO2001054701A1/fr
Publication of WO2001054701A9 publication Critical patent/WO2001054701A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La présente invention concerne un procédé qui permet d'arrêter la thérapie antirétrovirale chez des sujets infectés par le virus VIH sans provoquer de rebond viral ou au moins un rebond viral retardé ou un point de consigne post-rebond réduit. Ce procédé consiste à réinduire les réponses immunitaires spécifiques au VIH à l'aide d'une stratégie vaccinale permettant d'induire à la fois l'immunité à médiation humorale et l'immunité à médiation cellulaire. La présente invention réalise un contrôle immunologique du virus infectieux persistant après l'interruption d'une thérapie antivirale. La stratégie vaccinale de cette invention est à la fois sans danger et immunogène chez la population infectée par le virus VIH étudiée.
PCT/US2001/002766 2000-01-31 2001-01-26 Vaccination de personnes infectees par le vih apres une therapie antiretrovirale a haute activite WO2001054701A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001233063A AU2001233063A1 (en) 2000-01-31 2001-01-26 Vaccination of hiv infected persons following highly active antiretroviral therapy
US10/182,067 US20040034209A1 (en) 2001-01-26 2001-01-26 Vaccination of hiv infected persons following highly active antiretrovial therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17927600P 2000-01-31 2000-01-31
US60/179,276 2000-01-31

Publications (2)

Publication Number Publication Date
WO2001054701A1 true WO2001054701A1 (fr) 2001-08-02
WO2001054701A9 WO2001054701A9 (fr) 2002-10-31

Family

ID=22655900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/002766 WO2001054701A1 (fr) 2000-01-31 2001-01-26 Vaccination de personnes infectees par le vih apres une therapie antiretrovirale a haute activite

Country Status (2)

Country Link
AU (1) AU2001233063A1 (fr)
WO (1) WO2001054701A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027835A2 (fr) * 2003-09-18 2005-03-31 Merck & Co., Inc. Immunisation therapeutique d'individus infectes par le vih
WO2007018550A3 (fr) * 2004-09-08 2007-11-29 Us Health Compositions et methodes pour detecter une infection par le vih-1/vih-2
WO2011035082A1 (fr) * 2009-09-17 2011-03-24 Sanofi Pasteur, Inc. Compositions immunologiques pour le vih
US7943375B2 (en) 1998-12-31 2011-05-17 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US8133494B2 (en) 2001-07-05 2012-03-13 Novartis Vaccine & Diagnostics Inc Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008539A1 (fr) * 1996-08-26 1998-03-05 Chiron Corporation Therapie de vaccination apres l'infection par le virus de l'immunodeficience humaine (vih)
WO2001008702A2 (fr) * 1999-07-28 2001-02-08 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008539A1 (fr) * 1996-08-26 1998-03-05 Chiron Corporation Therapie de vaccination apres l'infection par le virus de l'immunodeficience humaine (vih)
WO2001008702A2 (fr) * 1999-07-28 2001-02-08 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotherapie traitant les personnes infectees par le vih utilisant des vaccins apres une multi-therapie

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
B. ROSENWIRTH ET AL.,: "An anti-HIV strategy combining chemotherapy and therapeutic vaccination", J MED PRIMATOL, vol. 28, no. 4-5, 1999, pages 195 - 205, XP000982240 *
GOTCH F ET AL: "THERAPEUTIC VACCINES IN HIV.1 INFECTION", IMMUNOLOGICAL REVIEWS,MUNKSGAARD,XX, vol. 170, 1999, pages 173 - 182, XP000982295, ISSN: 0105-2896 *
M. JOHN ET AL.,: "Control of HIV replication by cytotoxic T-lymphocyte responses", JOURNAL OF HIV THERAPY, vol. 4, no. 4, 1999, pages 91 - 97, XP000982254 *
MACGREGOR R R ET AL: "FIRST HUMAN TRIAL OF A DNA-BASED VACCINE FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION: SAFETY AND HOST RESPONSE", JOURNAL OF INFECTIOUS DISEASES,CHICAGO, IL,US, vol. 178, no. 1, July 1998 (1998-07-01), pages 92 - 100, XP000982247, ISSN: 0022-1899 *
PIALOUX ET AL: "A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)", AIDS RESEARCH AND HUMAN RETROVIRUSES,US,MARY ANN LIEBERT, vol. 11, no. 3, 1995, pages 373 - 381, XP002079474, ISSN: 0889-2229 *
R. HOFF AND J. MCNAMARA: "Therapeutic vaccines for preventing AIDS : their use with HAART", THE LANCET, vol. 353, 22 May 1999 (1999-05-22), pages 1723 - 1724, XP002168002 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943375B2 (en) 1998-12-31 2011-05-17 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US8133494B2 (en) 2001-07-05 2012-03-13 Novartis Vaccine & Diagnostics Inc Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2
JP2007515386A (ja) * 2003-09-18 2007-06-14 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖ感染個体の治療用免疫化
WO2005027835A3 (fr) * 2003-09-18 2007-08-16 Merck & Co Inc Immunisation therapeutique d'individus infectes par le vih
WO2005027835A2 (fr) * 2003-09-18 2005-03-31 Merck & Co., Inc. Immunisation therapeutique d'individus infectes par le vih
US8722324B2 (en) 2004-09-08 2014-05-13 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides
EP2295974A1 (fr) * 2004-09-08 2011-03-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions et procédés pour la détection d'une infection par VIH-1/VIH-2
US7888003B2 (en) 2004-09-08 2011-02-15 The United States Of America As Represented By The Department Of Health And Human Services Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
WO2007018550A3 (fr) * 2004-09-08 2007-11-29 Us Health Compositions et methodes pour detecter une infection par le vih-1/vih-2
US9121855B2 (en) 2004-09-08 2015-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
WO2011035082A1 (fr) * 2009-09-17 2011-03-24 Sanofi Pasteur, Inc. Compositions immunologiques pour le vih
AU2010295497B2 (en) * 2009-09-17 2014-10-09 Global Solutions For Infectious Diseases Immunological compositions for HIV
EP2987500A1 (fr) * 2009-09-17 2016-02-24 Sanofi Pasteur Inc. Compositions immunologiques pour le vih

Also Published As

Publication number Publication date
AU2001233063A1 (en) 2001-08-07
WO2001054701A9 (fr) 2002-10-31

Similar Documents

Publication Publication Date Title
MacGregor et al. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev
Pialoux et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI)
EP1784416B1 (fr) Vaccins contre le sida comprenant des constructions d'acides nucleiques cmv/r
Boyer et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial
US7771729B2 (en) Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors
KR102159626B1 (ko) 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물
Gupta et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A
KR20000052649A (ko) 사람의 면역결핍증비루스 감염의 예방 및 치료를 위한 알이브이
WO2004058278A1 (fr) Virus de la vaccine recombinants exprimant il-15 et methodes d'utilisation desdits virus
AU2001259291A1 (en) Improved immunogenicity using a combination of DNA and vaccinia virus vector vaccines
Bachelez et al. Oligoclonal expansion of HIV-specific cytotoxic CD8 T lymphocytes in the skin of HIV-1-infected patients with cutaneous pseudolymphoma.
US20090169503A1 (en) Dna-based vaccination of retroviral-infected individuals undergoing treatment
US20040034209A1 (en) Vaccination of hiv infected persons following highly active antiretrovial therapy
Buge et al. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge
WO2001054701A1 (fr) Vaccination de personnes infectees par le vih apres une therapie antiretrovirale a haute activite
AU779494B2 (en) Immunotherapy in HIV infected persons using vaccines after multi-drug treatment
Vagenas et al. Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239
Jirathitikal et al. Safety and efficacy of an oral HIV vaccine (V-1 Immunitor) in AIDS patients at various stages of the disease
US20060094006A1 (en) Immunotherapy regimens in hiv-infected patients
Ansari et al. Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS
Cosma Use of the regulatory protein Nef for vaccination against HIV-1
Jefferys Immune-based therapies and preventive technologies pipeline
Mosley et al. 2.3 HIV-1 vaccines
Jefferys Immune-Based Therapies and Preventive Technologies Pipeline 2006
WO2004043490A1 (fr) Schema posologique pour vaccin antivariolique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10182067

Country of ref document: US

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/11, 5/11, 9/11 AND 11/11, DRAWINGS, REPLACED BY NEW PAGES 1/11, 5/11, 9/11 AND 11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP